Total bilirubin ? 1.5 x ULN (unless has Gilbert's syndrome)
Re-registration: total bilirubin =< 1.5 x ULN in absence of Gilbert disease (total bilirubin =< 3 x ULN with Gilbert); if hyperbilirubinemia is clearly attributed to liver metastases, total bilirubin =< 3 x ULN is permitted
Total bilirubin =< 1.5 x ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 x ULN), within 4 weeks of randomization
Within 10 days of treatment initiation: Bilirubin =< 1.5 X IULN\r\n* Bilirubin > 1.5 x ULN is allowed in subjects with conjugated bilirubin disorder or Gilbert's syndrome
Bilirubin ? 1.5 × ULN unless evidence of Gilbert's disease in which case < 3 x ULN
Bilirubin < 1.5 × ULN except in patients with Gilbert's disease Renal Function
Total bilirubin > 1.5 times ULN (patients with confirmed Gilbert's syndrome may be included in the study)
Bilirubin ? 1.5 x ULN (unless considered due to Gilbert's syndrome or hemolysis)
Bilirubin =< 1.5 x ULN (unless documented Gilbert's disease), within 14 days of registration
Bilirubin ? 2.5 × ULN (? 4 × ULN for subjects with Gilbert's disease);
Patients with hyperbilirubinemia clinically consistent with an inherited disorder of bilirubin metabolism (e.g., Gilbert syndrome) will be eligible at the discretion of the principal investigator if total bilirubin is =< 1.5 X ULN
Total bilirubin less than or equal to 1.5 X ULN except for unconjugated hyperbilirubinemia of Gilbert's syndrome
Serum bilirubin > 1.5 × ULN; bilirubin up to 3 x ULN is permitted in individuals with documented liver involvement by lymphoma or if due to known Gilbert syndrome or other organ system that may place the patient at undue risk to undergo treatment
Total bilirubin =< 1.5 x ULN within 28 days of treatment initiation and must be independent of hematopoietic growth factor support\r\n* Note: patients with hyperbilirubinemia clinically consistent with an inherited disorder of bilirubin metabolism (eg, Gilbert syndrome) will be eligible at the discretion of the principal investigator
total bilirubin must be ? ULN for the lab unless the patient has a bilirubin elevation > ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; and
Total bilirubin ? 1.5 × institutional ULN (total bilirubin of ? 3 x institutional ULN in subjects with documented Gilbert's syndrome).
Total serum bilirubin =< 1.5 x ULN unless the patient has documented Gilbert syndrome
Obtained within 14 days prior to registration: Total bilirubin =< 1.5 ULN (unless documented Gilbert's disease)
Total bilirubin (TBL) < 2x ULN (unless Gilbert's disease or if liver involvement with lymphoma)
Within 14 days of randomization: Bilirubin =< ULN (unless documented Gilbert's disease)
Total bilirubin ?1.5 times the ULN (or ?3 x ULN, if patient has Gilbert syndrome)
Total bilirubin < 1.5 x ULN (or =< 3 x ULN for patients with documented Gilbert syndrome)
Total bilirubin =< 1.5 x ULN\r\n* Except in the case of Gilbert disease, in which case total bilirubin must be =< 3 x ULN
Total serum bilirubin ? 1.5 x ULN, (except for patients with known Gilbert's Syndrome ? 3 x ULN is permitted)
Within 4 weeks before enrollment: Total bilirubin =< 2.5 x ULN; except if the elevation is due to Gilbert's syndrome
Total serum bilirubin < 1.5 x ULN, unless the patient has documented Gilbert syndrome
Within 14 days prior to registration: Bilirubin =< 1.5 x ULN; for patients with Gilbert's syndrome, bilirubin =< 3 x ULN is acceptable
Bilirubin =< 1.5 x ULN (unless documented Gilbert's disease) within 14 days of cycle 1 day 1
Total bilirubin ?1.5 × ULN except for unconjugated hyperbilirubinemia or Gilbert's syndrome
• Bilirubin ? 1.5 times institutional ULN; does not apply to patients diagnosed with Gilbert's syndrome.
Total serum bilirubin =< 1.5 x ULN unless the patient has documented Gilbert syndrome. If organ function abnormalities are considered due to tumor, total serum bilirubin must be =< 2 x ULN
Liver function: ALT and AST ? 2.5 × ULN; Total bilirubin ? 1.5 × ULN (or ? 3 times ULN for subjects with documented Gilbert's syndrome or for whom indirect bilirubin concentrations suggest an extra-hepatic source of elevation)
Total bilirubin ?1.5 x ULN (does not include patients with Gilbert's Disease)
Total bilirubin > 1.5 x ULN (Patients with a history of Gilbert's syndrome may participate if total bilirubin is less than or equal to 1.5 x ULN and the AST/ALT and alkaline phosphatase meet the protocol-specified levels for eligibility)
Total bilirubin is less than or equal to ULN, except the case in which the elevated total bilirubin is not a sign of liver disease, such as the Gilbert Syndrome, in which case a total bilirubin less than or equal to 2 x ULN is acceptable
Total bilirubin ? 1 x ULN (unless elevated due to Gilbert's syndrome or extrahepatic source as denoted by increased indirect bilirubin fraction. Subjects with ?1 x ULN will be tested for direct bilirubin fraction so that the indirect fraction can be calculated).
Total serum bilirubin ?1.5 × ULN, unless due to Gilbert's syndrome
Total bilirubin < 1.5 times ULN unless due to Gilbert's disease
ADDITIONAL CRITERIA FOR STUDY CONTINUATION: Total bilirubin =< 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin =< 2.0 x ULN)
Total bilirubin (T-Bil) =< 1.5 X ULN (prior diagnosis or past history consistent with Gilbert's syndrome is an exception)
Bilirubin equal or less than 1.5 (unless Gilbert's syndrome)
Total bilirubin > 1.5 x ULN (or > 3 x ULN for patients with documented Gilbert syndrome)
Total bilirubin >= 1.5 x ULN (subjects with Gilbert's syndrome can have bilirubin of up to 1.5 x ULN), OR
Serum bilirubin < ULN (exception of Gilbert disease)
Total bilirubin =< 2 x ULN (except patients with documented Gilbert's syndrome)
Hepatic Parameters: Total Bilirubin </= ULN; Alkaline Phosphatase </= 2 x ULN; AST and ALT </= 2 x ULN If the patient has a history of Gilbert's Syndrome, check direct and indirect bilirubin. If in the judgment of the attending medical oncologist it is safe to treat the patient, the patient will be considered eligible for this criteria.
Total serum bilirubin?1.5 x ULN, (except for patients with known Gilbert's Syndrome?3 x ULN is permitted)
Total bilirubin < 3 x ULN (except if confirmed history of Gilbert's disease)
bilirubin < 1.5 ULN, excluding Gilbert's syndrome
Total bilirubin > ULN (except in patients diagnosed with Gilbert's disease).
Total Bilirubin ? 1.0 x ULN (unless elevated secondary to benign conditions such as Gilbert's disease)
Total bilirubin =< 2 x ULN or =< 3 x ULN if Gilbert's disease).
Bilirubin =< 1.5 x ULN (=< 3 x ULN for patients with Gilbert syndrome)
Total bilirubin =< 2 x ULN (patients with Gilbert syndrome may be included at the discretion of the principal investigator [PI] or where hemolysis has been excluded)
Total bilirubin =< 1.5 x ULN; unless presence of Gilbert's syndrome, liver involvement by CLL or MM, or stable chronic liver disease per investigator's assessment
Total bilirubin < 1.5 X ULN; patients with Gilbert's disease are exempt from this criteria
Bilirubin less than or equal to 1.5 (except if due to Gilbert's disease)
Total serum bilirubin ?2.0 x ULN unless the subject has documented Gilbert syndrome;
Total serum bilirubin ? 1.5 x ULN unless the patient has documented Gilbert syndrome and AST and ALT ? 2.5 x ULN.
T.Bili. ? 1.5 x ULN (except in patients diagnosed with Gilbert's disease).
Total serum bilirubin ? 2.0 × ULN (unless the subject has documented Gilbert Syndrome)
Serum total bilirubin ?1.5 x ULN (unless subject had documented Gilbert's Syndrome)
Total bilirubin ? 2.0 X ULN, or ? 3.0 X ULN (for patients with Gilbert's Syndrome)
Patients with Gilbert syndrome and bilirubin < 2 x ULN and normal AST/ALT
Bilirubin ? 1.5 × ULN except for cases of documented or suspected Gilbert's disease, in which bilirubin must be ? 5 × ULN
Serum bilirubin =< 1.5 x ULN or =< 3.0 x ULN for patients with Gilbert syndrome or documented hepatic involvement
Total bilirubin < 1.5 x ULN (except for subjects with documented Gilbert's syndrome)
Total bilirubin =< 2 x ULN (except patients with documented Gilbert's syndrome)
Total bilirubin <1.5 x the institutional ULN, unless the subject has documented unconjugated bilirubin disorder such as Gilbert's syndrome.
Total bilirubin =< 1.5 x ULN (excepting Gilbert's syndrome)
Total bilirubin within normal limits (WNL) for the institution, unless the bilirubin abnormality is considered due to Gilbert's syndrome.
bilirubin less than or equal to 1.5 × ULN for all subjects age 75 and older* Subjects who are less than 75 years of age must have a bilirubin of less than 3.0 × ULN * Unless considered due to leukemic organ involvement. Note: Subjects with Gilbert's Syndrome may have a bilirubin greater than 1.5 × ULN per discussion between the investigator and AbbVie medical monitor.
Total serum bilirubin ?1.5 x ULN (<3.0 x ULN for participants with Gilbert syndrome)
Total bilirubin within normal ranges unless associated with hepatobiliary metastases or Gilbert syndrome, then total bilirubin ? 2 x ULN
Total bilirubin ? 1.5 × institutional ULN except in the presence of Gilbert Syndrome
Total bilirubin =< 1.5 x ULN (patients with elevated bilirubin due to Gilbert's disease will not be excluded)
Total bilirubin =< 1.5 X ULN (except in patients with Gilbert's)
Total bilirubin < 1.5 x ULN\r\n* Does not apply to patients with isolated hyperbilirubinemia (e.g., Gilbert's disease) grade < 3
Bilirubin ? 1.5 × ULN except for subjects with documented Gilbert's disease, ? 2.5 × ULN;
Total bilirubin ?1.5 x ULN (except for subjects with documented Gilbert's syndrome)
Total serum bilirubin ? 2.0 × ULN (unless the subject has documented Gilbert Syndrome)
Total bilirubin =< 1.5 x ULN unless the patient has documented Gilbert syndrome
Serum bilirubin ? 2 x ULN unless due to Gilbert's syndrome or hemolysis or considered to be related to leukemia;
Total bilirubin values <1.5 x ULN unless the bilirubin is principally unconjugated (in the context of hemolysis) or there is documented Gilbert's disease.
Total bilirubin < 1.5 × ULN (except for subjects with documented Gilbert's syndrome)
Bilirubin ?2.0 times ULN, unless participant has known Gilbert's syndrome
Bilirubin ? 2.0 times ULN, unless subject has known Gilbert's syndrome
For patients with Gilbert's syndrome total bilirubin > 2.5 x ULN
Total bilirubin ?1.5 x ULN, unless secondary to Gilbert's disease
Total bilirubin >1.5x ULN (unless due to Gilbert's Syndrome)
Serum bilirubin < 1.5 x ULN unless due to Gilbert's syndrome. o Serum bilirubin ? 1.0 x ULN unless due to Gilbert's syndrome, Treatment Arm B only (CC-122 in combination with ibrutinib)
Serum bilirubin =< 1.5 x ULN (unless secondary to Gilbert's disease)
Total serum bilirubin ? ULN unless due to Gilbert's Syndrome;
Bilirubin ? 1.5 × ULN except for cases of documented or suspected Gilbert's disease, in which bilirubin must be ? 5 × ULN
Total bilirubin ? 1.5 × ULN except in cases of Gilbert's disease and liver metastases.
Total bilirubin ? 1.5 X ULN. Patients with elevated bilirubin known to be due to Gilbert's disease may be enrolled after approval from the medical monitor, and
Bilirubin ? 1.5 × ULN except for cases of documented or suspected Gilbert's disease, in which bilirubin must be ? 5 × ULN
Total bilirubin ? 1.5 × ULN except subjects with documented Gilbert's syndrome (> 3 × ULN) or liver metastasis, who must have a baseline total bilirubin ? 3.0 mg/
Total bilirubin > 1.5× the ULN for the institution, unless considered due to Gilbert's Syndrome
Total bilirubin ?2.0 times the ULN for the institution, unless considered due to Gilbert's syndrome;
Total bilirubin ?2 x ULN (?5 x ULN if considered due to Gilbert's syndrome or hemolysis)
Total bilirubin < 1.5 x ULN (< 3.0 x ULN for subjects with documented Gilbert's Disease or for whom the indirect bilirubin level suggests an extrahepatic source of elevation);
Patient has > 1.5 x ULN total bilirubin, unless history of Gilbert's syndrome
Total bilirubin ?1.5 X ULN unless considered due to Gilbert's syndrome
Total bilirubin ?1.5X ULN, unless considered due to Gilbert's syndrome
Total bilirubin ?2X ULN, unless considered due to Gilbert's syndrome
Total bilirubin ?2X ULN, unless considered due to Gilbert's syndrome
Total bilirubin > 1.5 x ULN (unless due to lymphoma or isolated, predominantly indirect hyperbilirubinemia due to Gilbert's syndrome)
Bilirubin equal or less than 1.5 (unless Gilbert's Syndrome)
Bilirubin =< ULN (unless documented Gilbert's disease), obtained within 14 days prior to treatment start
- Total bilirubin < 1.5 x ULN (< 3 x ULN in patients with known/suspected Gilbert's disease)
Total bilirubin ?1.5 x ULN, except in subjects with documented Gilbert's Syndrome, who must have a total bilirubin ?3 x ULN
- Total bilirubin < 1.5 x ULN (< 3 x ULN in patients with known/suspected Gilbert's disease)
Total bilirubin >1.5 x ULN (unless Gilbert's syndrome or extrahepatic source as denoted by increased indirect bilirubin fraction)
Bilirubin >1.5 x ULN, unless prior diagnosis and documentation of leukemic organ involvement, ongoing hemolysis, or Gilbert's syndrome